iPremom develops prenatal diagnostic solutions based on the identification of early molecular alterations associated with pregnancy complications. Our approach integrates:
Endometrial and placental biology
Transcriptomic analysis
Multi-omics technologies
Liquid biopsy (cfRNA)
Predictive models based on artificial intelligence
The aim is to detect biological alterations before the appearance of clinical symptoms, allowing for early intervention.
These alterations generate a molecular signature detectable in maternal blood through cfRNA.
An approach centred on the uterus
Our research has identified a key mechanism in the development of preeclampsia:
01 — Decidualisation
Decidualisation prepares the uterus for embryonic invasion and placental development. We have demonstrated the maternal contribution to severe preeclampsia through defective decidualisation.
02 — Placentation
The placenta provides nutrients and oxygen to the embryo.
Defective decidualisation alters maternal-fetal communication during placentation.
03 — Molecular signal
cfRNA molecules reflect dynamic changes in the biology of pregnancy.
Our technology makes it possible to detect these signals and predict complications before the appearance of symptoms.
iPremom's technology is based on an integrated pipeline:
Liquid biopsy
Extraction of circulating cell-free RNA (cfRNA) from maternal plasma
Molecular processing
Library preparation Sequencing using NGS (Next-Generation Sequencing) Quality control
Bioinformatic analysis
Processing of transcriptomic data
Predictive model
Algorithm based on artificial intelligence Generation of an individualised preeclampsia risk during the first trimester
iPremom's technology is based on an integrated pipeline: The system is implemented as: Software-as-a-Medical-Device (SaMD) Compliant with ISO 13485 and IEC 62304 standards
Scientific development
The development of the platform has been carried out progressively through:
In vitro models of decidualisation
Animal models
Endometrial transcriptomic studies
Multi-omics analyses
Validation through liquid biopsy
This approach has made it possible to establish a direct relationship between: biological origin → molecular signal → detection in blood